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Abstract 
Background: Macular edema and detachment at the first day after an uneventful cataract surgery is very rare, and 
has been reported previously with the use of high concentrations of intra-cameral cefuroxime. However, we hereby 
reported two cases of macular edema with extensive serous retinal detachment the first day after an uneventful 
phacoemulsification with intra-cameral injection of a standard dose of cefuroxime during the procedure.
Case presentation: A 68-year-old female and a 63-year-old male without any special history both underwent 
an uneventful phacoemulsification surgery and 1 mg/0.1 ml of cefuroxime solution was injected into the anterior 
chamber at the end of the procedure. Macular edema with extensive serous retinal detachment around macula and 
optic disc area were observed the first day after surgery. Without surgical intervention, a quick recovery of the macular 
edema and retinal detachment was observed by spectral domain optical coherence tomography 1 week later in both 
cases.
Conclusion: We presume that the retina injury in the two cases may be attributed to cefuroxime toxicity even under 
a use of a standard dose. But the retinal damages are restorable and routine anti-inflammatory treatment is enough.
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Background
Macular edema is one of the most common compli-
cations after cataract surgery that causes unfavorable 
visual outcomes and usually occurs in the surgical eye 
4–16  weeks after the procedure [1, 2]. Acute macular 
edema with retinal detachment after cataract surgery is 
very rare, and has been reported previously with the use 
of high concentrations of intra-cameral cefuroxime [3, 4]. 
Cefuroxime is commonly used during phacoemulsifica-
tion procedure [5] and has been proved to be safe with 
a standard dose previously [6–8]. However, we hereby 
report two cases of macular edema with extensive serous 
retinal detachment that was immediately detected by 
spectral domain optical coherence tomography (SD-
OCT) the first day after an uneventful phacoemulsifica-
tion with intra-cameral injection of standard doses of 
cefuroxime during the procedure. We presume that the 
retina injury in the two cases may be attributed to cefuro-
xime toxicity even under a use of a standard dose.
Case presentation
Case 1
A 68-year-old female had an uncomplicated phacoemul-
sification surgery with folded in-the-bag intraocular lens 
(IOL) implantation in her left eye. Her systemic and oph-
thalmic histories were unremarkable. No diabetic, uveitis 
or any other remarkable retinal history was found prior 
to the surgery. Preoperatively, the refractive errors of her 
right and left eyes were −4.0 and −4.5 diopters (D), with 
axial lengths of 24.12 and 24.37  mm, respectively. The 
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best-corrected visual acuity was 20/33 in the right and 
20/40 in the left eye. The patient’s anterior segment and 
fundus were normal in both eyes, as revealed by regular 
examination. The surgery was performed using an Infiniti 
phacoemulsification unit (Alcon, Inc.). The nucleus chop-
ping time was 5.8  s, and the average power was 6.8  %. 
A +18  D folded IOL (Acrysof SN60AT Alcon, Inc) 
was implanted in-the-bag. The surgery was completed 
without complications. At the end of the procedure, 
1 mg/0.1 ml of cefuroxime solution was injected into the 
anterior chamber. We perform our dilution in the oper-
ating room: the nurse takes 750 mg of preservative-free 
vial cefuroxime and adds 7.5 ml of balanced salt solution 
(BSS), and then, the surgeon takes 0.1 ml of this first solu-
tion and adds another 0.9 ml of BSS to obtain the second 
solution. 0.1 ml of the second solution is finally injected 
in the anterior chamber of the patient. The patient is 
therefore supposed to receive 0.1  ml of 10  mg/ml solu-
tion of intra-cameral cefuroxime. The total length of the 
surgical time was approximately 10 min.
The first day after the operation, the visual acuity in 
her left eye was 20/200. There were no signs of remark-
able inflammation or abnormality in the anterior seg-
ment, as well as in the vitreous. Fundus examination 
showed no foveal reflection in the macula. Diffuse reti-
nal edema affected most of the posterior pole. Retinal 
wrinkles were found around the macula and disc area. 
No significant abnormality was found in the peripheral 
retina. SD-OCT (Carl Zeiss Meditec, Dublin, CA, USA) 
scanning was immediately performed and showed mac-
ular edema, especially at the outer nuclear layer, with 
extensive shallow serous retinal detachment around 
macula and optic disc area (Fig. 1). The retinal thickness 
of the fovea was 750  μm. No significant abnormality 
was found in the choroids and the subfoveal choroidal 
thickness was 350  μm. Vitreomacular traction was not 
found in the SD-OCT image. Topical dexamethasone 
0.1  %/tobramycin 0.3  % (Tobradex®) eye drops and 
pranoprofen (Senju Pharmaceutical Co. Ltd) were pre-
scribed four times a day. After 1 week of treatment, the 
patient’s vision in her left eye had improved to 20/20. 
The macular retina was scanned with the same area 
by SD-OCT and the image showed that the retinal 
thickness of the fovea returned within a normal range 
(194 μm), and the subfoveal choroidal thickness seemed 
not changed a lot (about 347 μm). The macular edema 
and subretinal fluid were absorbed completely. The inte-
grated ellipsoid zone was preserved in the outer retina 
(Fig.  2). No recurrence of macular edema or retinal 
detachment was noted at the last follow-up (4  months 
post-operative). 
Case 2
A 63-year-old male underwent an uneventful phaco-
emulsification surgery with folded in-the-bag IOL 
implantation in the left eye. The systemic and ophthal-
mic histories were unremarkable. Preoperatively, the 
refractive error of his left eye was −2.75 D with an axial 
length of 23.93 mm. The best corrected visual acuity was 
20/200. The right eye had IOL implanted 1 year ago with 
good visual acuity of 20/20. Findings of anterior segment 
and fundus examination were normal in both eyes. The 
phacoemulsification surgery was performed by the same 
doctor as in case 1. The nucleus chopping time was 32 s 
and the average power was 16.8 %. A +20.0 D folded IOL 
(Acrysof SN60AT Alcon, Inc) was implanted in-the-bag. 
The surgery was completed without complications. At 
the end of the procedure, 1 mg/0.1 ml of cefuroxime solu-
tion (diluted as case 1) was also injected into the anterior 
chamber. The total length of the surgical time was about 
12 min.
The first day after the operation, the visual acuity in 
his left eye was finger count. No remarkable inflamma-
tions or abnormalities were found in the anterior seg-
ment and vitreous by slit-lamp examination. Fundus 
manifestation was similar to case 1. SD-OCT image also 
Fig. 1 Image of spectral domain optical coherence tomography (SD-OCT) on one day post-operation (case 1). The SD-OCT image demonstrated 
macular edema most manifested at the outer nuclear layer and shallow serous retinal detachment around the macula (a) and optic disc area (b)
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showed the same macular edema as case 1 (Fig. 3a). The 
retina thickness of the fovea was 794  μm. No signifi-
cant abnormality was found in the choroids. The same 
drugs as in case 1 were adopted four times a day. After 
1  week treatment, the patient’s visual acuity improved 
to 20/20. SD-OCT revealed macular edema and sub-
retinal fluid were absorbed completely. The integrated 
ellipsoid zone was preserved in the outer retina (Fig. 3b). 
The retinal thickness of the fovea returned within a nor-
mal range (174 μm). No recurrence of macular edema or 
retinal detachment was noticed until the last follow-up 
(3 months after surgery).
Conclusions
With modern cataract surgical techniques, the inci-
dence of post-surgical cystoid macular edema (CME) 
has decreased to 0.1–2.35  % [9]. Several mechanisms 
may contribute to such macular edema, including the 
effects of vitreoretinal traction, light damage, produc-
tion of prostaglandins and intraoperative complications 
[1, 10]. The rate of macular edema after cataract surgery 
is increased in the presence of diabetic retinopathy and 
uveitis [11, 12]. However, the two cases were notable for 
its unremarkable retinopathy and lack of history of diabe-
tes or uveitis.
Fig. 2 SD-OCT images of case 1 One week post-operation. Macular edema and subretinal fluid was absorbed and the central foveal thickness 
resumed to normal (a). The subretinal fluid was also absorbed around optic disc (b)
Fig. 3 SD-OCT images of case 2. The SD-OCT image demonstrated macular edema most manifested at the outer nuclear layer and extensive 
shallow serous retinal detachment around the macula (a) and optic disc area (c) the first day after surgery. Macular edema and subretinal fluid was 
absorbed and the central foveal thickness resumed to normal at 1 week post-operation (b). The subretinal fluid was also absorbed around optic 
nerve head at 1 week post-operation (d)
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Jurecka et  al. [13] found a positive statistical correla-
tion between the real phacoemulsification time and the 
increase in macular retinal thickness after surgery. In the 
present cases, the real phacoemulsification time was not 
long, and the average power was low.
Cefuroxime toxicity may be one of the cause of macular 
edema and detachment. The recommended dose of intra-
cameral cefuroxime injection is 0.1 ml of 10.0 mg/ml solu-
tion. The fact that excessive cefuroxime solution injections 
into the anterior chamber can cause early serous macular 
detachment and edema has been reported previously [3, 
4]. The reported dose has been varied from 20 to 50 mg/
ml. However, recently, Kontos et al. [14] reported a case 
with acute serous macular detachment and macular 
edema after a standard dose of subconjunctival cefuro-
xime injection in the phacoemulsification. Faure et al. [15] 
even reported a case occurred retinal toxicity the second 
day after surgery with a standard dose of intra-cameral 
cefuroxime injection in France. In the present two cases in 
China, early macular edema and extensive retinal detach-
ment were found immediately the first day after surgery 
with a standard dose of intra-cameral cefuroxime injec-
tion at the end of the phacoemulsification. The visual loss 
was earlier in the present two cases than that of Faure 
et al. report. Though the visual loss time after surgery had 
little difference, the manifestations of these cases were 
similar. The interval time between the present two cases 
was about one month. No abnormality was found dur-
ing the drug dilution process. Thus, we presume that the 
retina injury in the two cases may be also attributed to 
cefuroxime toxicity even under a use of a standard dose.
In these two cases, the location of the edema was unu-
sual: Typically retinal edema was located in the outer 
plexiform layer. However, in these cases the outer plexi-
form layer appeared to be spared and the outer nuclear 
layer had large edema. There was extensive subretinal fluid 
without debris. These OCT characteristics were similar to 
the manifestation that has been identified in OCT of the 
retinal toxicity caused by excessive cefuroxime solution 
injections [3, 4], and might provide a marker for cefuro-
xime toxicity. The mechanism of this pattern of edema is 
unclear. The electroretinogram (ERG) results of animal 
experiments [16] and human clinical observation [15] 
prompted cefuroxime was toxic to retina, and may effect 
the Müller cell function. Previous study [3, 4] reported that 
fluorescein angiograms (FA) showed diffuse leakage with-
out abnormal retinal perfusion in cefuroxime toxic eyes 
and indicated that the blood–retinal barrier at the retinal 
pigment epithelium (RPE) may be disrupted. It is a limita-
tion that the FA was not obtained in the present two cases, 
but the SD-OCT images may suggest that the primary 
lesions were localized at the outer retinal and RPE.
Clear vitreous haze has been reported in ocular toxicity 
after intra-cameral injection of very high doses of cefuro-
xime during cataract surgery [4]. But, no sign of remarka-
ble inflammation in the vitreous was found in the present 
cases. No abnormality in vitreous has also been reported 
by Buyukyildiz in two cases of retinal toxicity caused by 
2 mg/0.1 ml cefuroxime intra-cameral injection [3]. The 
dose of cefuroxime injection was much higher in Delyfer 
et al. study [4] than the presented cases and Buyukyildiz 
et  al. cases [3]. The different doses of cefuroxime injec-
tion during cataract surgery may lead to the different 
findings in vitreous.
Topical nonsteroidal anti-inflammatory drugs and cor-
ticosteroids have been reported to be effective and safe 
therapy for preventing post-surgical ocular inflamma-
tory and macular edema [17–20]. Thus combination of 
nonsteroidal anti-inflammatory drugs and corticoster-
oids was applied in the present cases topically as routine 
anti-inflammation treatment after phacoemulsification. 
The SD-OCT image revealed a quick recovery from the 
macular edema without any special surgical intervention 
1  week later. Delyfer et  al. [4] also reported that retinal 
injury and visual dysfunction induced by intra-cameral 
excessive cefuroxime injection were able to recover to 
normal without surgery intervention after 6  weeks. The 
recovery time was shorter in the present cases than pre-
vious report. That may be due to the much lower con-
centration of cefuroxime solution used in the two cases. 
These results suggest that early macular edema with 
extensive serous retinal detachment which may be attrib-
uted to cefuroxime toxicity are restorable. Routine anti-
inflammatory treatment is sufficient and do not require 
excessive interventions.
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